ADC Corporate-Presentation_JPMorgan_01122025.pdf

《ADC Corporate-Presentation_JPMorgan_01122025.pdf》由会员分享，可在线阅读，更多相关《ADC Corporate-Presentation_JPMorgan_01122025.pdf（26页珍藏版）》请在三个皮匠报告上搜索。

1、JPMorgan 43rdAnnual Healthcare ConferenceJanuary 20252Forward-Looking StatementsThis presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA(ADC Therapeutics“,“we”or“us”)for informational purposes only and not for any other purpose.Nothing contained in this pres

2、entation is,or should be construed as,a recommendation,promise or representation by the presenter or ADC Therapeutics or any officer,director,employee,agent or advisor of ADC Therapeutics.This presentation does not purport to be all-inclusive or to contain all of the information you may desire.Infor

3、mation provided in this presentation and any accompanying oral presentation speak only as of the date hereof.This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.In some cases you can identify f

4、orward-looking statements by terminology such as“may”,“will”,“should”,“would”,“expect”,“intend”,“plan”,“anticipate”,“believe”,“estimate”,“predict”,“potential”,“seem”,“seek”,“future”,“continue”,or“appear”or the negative of these terms or similar expressions,although not all forward-looking statements

5、 contain these identifying words.Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.Factors that may cause such differences include,but are not limited to:the expected cash runway into mid-2026;the Company

6、s ability to grow ZYNLONTA revenue in the United States;the ability of our partners to commercialize ZYNLONTA in foreign markets,the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA in foreign jurisdictions;the